Poland· PL-100416460
Jivi
A coagulation factor viii product containing damoctocogum alfa. czynnik viii krzepnięcia krwi ludzki rekombinowany, registered in Poland by Bayer AG. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor viii is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Coagulation factor viii · ATC B02BD02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Damoctocogum alfa. Czynnik VIII krzepnięcia krwi ludzki rekombinowany
- Manufacturer
- Bayer AG
- Country
- Poland (PL)
- ATC code
- B02BD02
- ATC class
- Coagulation factor VIII
- Defined daily dose
- 1 TSD, E
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for coagulation factor viii.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor viii · interactions on record
4 records
- 2 severe
- 2 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- EmicizumabB02BX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B02BD02
Coagulation factor viii, as other registers publish it.
- PolandAdvateTakeda Manufacturing Austria AG
- IcelandAdvateTakeda Manufacturing Austria AG
- PolandAdvateTakeda Manufacturing Austria AG
- PolandAdvateTakeda Manufacturing Austria AG
- PolandAdvateTakeda Manufacturing Austria AG
- FinlandAdvateAbacus Medicine A/S
- PolandAdvateTakeda Manufacturing Austria AG
- IcelandAdvateTakeda Manufacturing Austria AG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c6b8c701-4c2b-4468-8384-41caafe8fafe GET /v1/drugs/c6b8c701-4c2b-4468-8384-41caafe8fafe?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "3000 j.m.",
"packaging": "Rpz ¦ EU/1/18/1324/005 ¦ 131267\n1 fiol. + 1 amp.-strzyk. + 1 zestaw do wstrzykiwań\nRpz ¦ EU/1/18/1324/010 ¦ 152598\n1 fiolka + 1 amp.-strzyk. + 1 zestaw do wstrzykiwań (1 opakowanie zbiorcze z 30 pojedynczymi opakowaniami)",
"substance": null,
"common_name": "Damoctocogum alfa. Czynnik VIII krzepnięcia krwi ludzki rekombinowany",
"pl_product_id": "100416460",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about coagulation factor viii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.